Comment
In The Lancet Haematology, Carsten Weishaupt and colleagues report the results of their study of 25 patients with livedoid vasculopathy who received treatment with rivaroxaban, an oral direct factor Xa antagonist that is mainly used for the treatment and prevention of thromboembolic diseases.1 For patients who did not improve with rivaroxaban, injectable enoxaparin could be used in the short term; if this lead to improvement, the patients were switched back to oral therapy with rivaroxaban, which was done for six of seven patients treated with enoxaparin. Overall, the use of rivaroxaban was associated with a substantial reduction of pain. Median visual analogue scale scores decreased from 65·0 (IQR 52·0–78·0) to 6·0 (1·0–14·0) after 12 weeks of treatment (p
In The Lancet Haematology, Carsten Weishaupt and colleagues report the results of their study of 25 patients with livedoid vasculopathy who received treatment with rivaroxaban, an oral direct factor Xa antagonist that is mainly used for the treatment and prevention of thromboembolic diseases.1 For patients who did not improve with rivaroxaban, injectable enoxaparin could be used in the short term; if this lead to improvement, the patients were switched back to oral therapy with rivaroxaban, which was done for six of seven patients treated with enoxaparin. Overall, the use of rivaroxaban was associated with a substantial reduction of pain. Median visual analogue scale scores decreased from 65·0 (IQR 52·0–78·0) to 6·0 (1·0–14·0) after 12 weeks of treatment (p
